Psoriatic arthritis: A review;Psoriasisarthritis: Ein Übersichtsartikel

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue 5, 2010, Pages 332-340

  Amherd Hoekstra, A ^a   Näher, Helmut ^a   Lorenz, Hanns Martin ^a   Enk, Alexander H ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

DMARD; IMID; Psoriatic arthritis; TNF alpha antagonist; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTHROPATHY; CHRONIC INFLAMMATION; CLINICAL FEATURE; DERMATOLOGY; DISEASE CLASSIFICATION; HUMAN; PATHOGENESIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOLOGY; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTING CELL; ARTHRITIS, PSORIATIC; COOPERATION; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INTERDISCIPLINARY COMMUNICATION; LYMPHOCYTE ACTIVATION; MULTIMODALITY CANCER THERAPY; PHYSIOTHERAPY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGEN-PRESENTING CELLS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERDISCIPLINARY COMMUNICATION; LYMPHOCYTE ACTIVATION; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85047685816     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07334_supp.x     Document Type: Review

References (36)

1. Mrowietz U, Reich K : Psoriasis - New Insights Into Pathogenesis and Treatment, Dtsch Arztebl Int 2009 106 (1-2 11 9.
2. http://www.rheuma-online.de
3. Wohlrab J (ed Psoriasisarthritis: in Trends Clin Exp Dermatol, Aachen, Shaker, 2005, vol 5.
4. Feyertag J, Dunky A : Arthritis psoriatica (Psoriasisarthritis), J Miner Stoffwechs 2005 12 (4 105 109.
5. FitzGerald O, Winchester R : Psoriatic arthritis: from pathogenesis to therapy, Arthritis Research and Therapy 2009, 11 : 214.
6. Winchester R : Genetics of psoriasis and psoriatic arthritis. In Psoriatic and Reactive Arthritis - A Companion to Rheumatology. Edited by Ritchlin CT, FitzGerald O.
7. Winchester R, Minevich G, Kane D, Bresnihan B, Greenberg D, FitzGerald O : Heterogenity of the psoriasis phenotype revealed by HLA class I haplotype associations in psoriatic arthritis and psoriasis. Clin Immunol 2008, 127 (suppl 1 S88 S89.
8. Gladman DD, Farewell VT, Kopciuk HA, Cook RJ. HLA antigens and progression in psoriatic arthritis. J Rheumatol 1998 25 : 730 733.
9. Radtke MA, Mössner R, Augustin M, Reich K : Psoriasis Arthritis, Klinik, Pathogenese und Diagnostik, Der Deutsche Dermatologe 5-2007.
10. Gota C, Calabrese L : Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003 36 : 511 518.
11. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973 3 (1 55 78.
12. Helliwell PS, Taylor WJ : Classification and diagnostic criteria for psoriatic arthritis. Annals of the Rheumatic Diseases 2005 64 (Supplement 2 ii3 ii8.
13. Brockbank J, Stein M, Schentag C, Gladmann DD. Characteristics of dac-tylitis in psoriatic arthritis (PsA). J Rheumatol 2001 28 (suppl 6 1416.
14. Gladmann DD, Strand V, Mease PJ, Antoni C, Nash P, Kavanaugh A. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 2005 64 (suppl II ii 115 6.
15. Mathies U : Diagnose und Klassifikationskriterien der Osteoarthropatica psoriatica. In : Wollina U, Hein G, Kopf B (Hrsg Psoriasis und Gelenkerkrankungen. Gustav Fischer Verlag
16. Bizarro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline intibody assay for rheumatoid arthritis. Clin Chem 2001 47 : 1089 1093.
17. Härle P, Hartung W, Lehmann P, Ehrenstein B, Schneider N, Müller H, Müller-Ladner U, Tarner I, Vogt T, Fleck M, Bongartz T. Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting, Z Rheumatol. 2009 May 21.
18. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001 19 : S17 S20.
19. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968 80 771 793.
20. http://www.awmf.de Therapie der Psoriasis vulgaris Kurzfassung ICD-10 Ziffer: L40.0.
21. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr., Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996 39 : 2013 2020. (Pubitemid 27009069)
22. Combe B, Goupille P, Kuntz J, Tebib J, Leote F, Bregeon C. Sulphasalazine in psoriatic arthritis; a randomized multi-centre placebo controlled trial. Br J Rheumatol 1996 35 : 664 668.
23. Rahman P, Gladmann DD, Cook RJ. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998 25 : 1957 1961.
24. Radtke MA, Mössner R, Augustin M, Reich K : Psoriasis-Arthritis -Therapeu-tische Strategien: je früher desto besser. Der Deutsche Dermatologe 2007, 6 : 407 410.
25. Black RL, O'Brian WM, VanScott EJ, Aurbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; double blind study on 21 patients. JAMA 1964 189 : 743 747.
26. Liang GC, Barr WG. Long term follow-up of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis. Arthritis Rheum 2001 44 : S121.
27. Scarpa R, Manguso F, Oriente F, Peluso R, Oriente P. Leflunomide in psoriatic polyarthritis: an Italian pilot study. Arthritis Rheum 2001 44 : S92.
28. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhauot J, Falk FG, Mease P Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arhtritis Rheum 2004 50 : 1939 1950.
29. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, Van Der Heijde D : The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Annals of the Rheumatic Diseases 2006 65 : 1038 1043.
30. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C : Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007 66 : 498 505.
31. Mease P. TNF-alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004 63 : 755 758. (Pubitemid 38850443)
32. Mease PJ. Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol, 2004 16 : 366 370.
33. ® (Inflixi-mab), Centocor, Leiden, Niederlande, Januar 2005.
34. Mease P, Gladmann DD Ritchlin C, Ruderman E, Steinfeld D, Choy E, Sharp JT, Ory PA, Perdok RJ, Weinberg MA : Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 2004 50 : 4097.
35. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colluci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted an-ticytokine therapy in patients with chronic heart failure. Circulation 2004 109 1594 1602.
36. Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol 2004 140 : 366.